'Major' breakthrough in Covid-19 drug
Pessors Ratko
Djukanovic, Stephen Holgate and Donna Davies discovered that people with asthma
and chronic lung disease lacked a protein called
interferon beta, which helps fight off the common cold. They worked out
that patients’ defences against viral infection could be boosted if the missing
protein were replaced. The academics created
a company, Synairgen, to turn their discoveries into treatments. It
floated on the stock market in 2004, but a deal with AstraZeneca to treat
viral infections in asthmatics fell through, and the shares collapsed.
https://www.theguardian.com/world/2020/jul/24/major-breakthrough-in-covid-19-drug-makes-uk-professors-millionaires
Fast-forward a few
years to the coronavirus pandemic, however, and suddenly any potential
therapeutics for breathing difficulties were in high demand. Richard Marsden,
Synairgen’s chief executive, said the company had been deeply involved in a
trial using the interferon beta drug to help people with chronic bronchitis or
emphysema. “[But] when the coronavirus pandemic emerged, even back in January
we realised that we might have an important role to play in defence against
this virus,” he said. “So we set about getting a clinical trial set up in
February and March in anticipation of the virus coming to the UK, [and] it did.
The trial was in place when people started to fill the hospitals up....
https://www.theguardian.com/world/2020/jul/24/major-breakthrough-in-covid-19-drug-makes-uk-professors-millionaires